Semaglutide
Semaglutide (GLP-1 receptor agonist peptide) · ≥98% (HPLC)
Semaglutide is a synthetic 31-residue lipidated GLP-1 receptor agonist peptide supplied as a characterized reference material for in-vitro receptor and analytical research. For Research Use Only. Not for human or veterinary use.
More in Metabolic signaling
Tirzepatide
Direct-lab pricing · up to 50% below comparable retail listings
Tirzepatide is a synthetic 39-residue lipidated dual GIP/GLP-1 receptor agonist peptide supplied as a characterized reference material for in-vitro receptor and analytical research. For Research Use Only. Not for human or veterinary use.
Retatrutide
Direct-lab pricing · up to 50% below comparable retail listings
Retatrutide (LY3437943) is a synthetic 39-residue lipidated triple-agonist peptide used as a characterized reference material for in-vitro study of GIPR, GLP-1R, and GCGR signaling. For research use only.
AOD9604
Direct-lab pricing · up to 50% below comparable retail listings
AOD9604 is a synthetic 16-residue fragment of human growth hormone (residues 176-191) supplied as a characterized reference material for in-vitro lipid-metabolism research, independent of the GH/IGF-1 axis. Research Use Only.
Research profile & documentation
- Why researchers study it
- Studied in vitro as a widely-referenced single-receptor GLP-1 agonist probe, frequently used as a comparative benchmark against multi-receptor incretin analogs in receptor-pharmacology literature.
- Mechanism themes in research
- GLP-1 receptor (GLP-1R) agonism and Gs/cAMP pathway activationFatty-diacid lipidation conferring albumin binding and extended in-vitro stabilityAib8 substitution imparting resistance to dipeptidyl-peptidase-4 cleavageComparative reference standard against dual/triple-agonist incretin analogs
- What the evidence does not establish
- Published references are in-vitro or pre-clinical and describe research context only. They do not establish safety, efficacy, or any outcome in humans or animals, and Get Peptides makes no such claims.
- Quality markers
- ≥98% (HPLC)MS identityLot COACold-chain
- What ships
- The sealed lot-controlled vial, a measured ampoule of bacteriostatic water, and a printed handling & reconstitution card — plus the per-lot COA. Everything to prepare it, in one box.
Semaglutide is a synthetic, lipidated 31-residue GLP-1 receptor agonist peptide supplied as a characterized reference material for in-vitro receptor pharmacology, analytical chemistry, and comparative incretin research. This overview separates molecular identity from clinical marketing language and keeps the material in a Research-Use-Only context.
Molecular identity
Semaglutide is built on a GLP-1-derived peptide backbone with sequence substitutions and a C18 fatty-diacid side chain attached through a linker to a lysine residue. Public compound records describe the material under CAS 910463-68-2, with a reported molecular formula of C₁₈₇H₂₉₁N₄₅O₅₉ and an approximate molecular weight of 4113.6 g/mol. Lot-specific identity should always be checked against the certificate of analysis rather than inferred from a catalog page.
Structural features
The Aib substitution at position 8 and the lipidated side chain are useful topics for structure–activity and peptide-stability studies. In the literature, these features are discussed in relation to protease resistance, receptor engagement, and albumin association. They also make semaglutide a useful comparator when researchers study how backbone changes and conjugation alter the behavior of class-B GPCR peptide ligands.
| Full name | Semaglutide (GLP-1 receptor agonist peptide) |
| Research theme | Metabolic signaling |
| CAS number | 910463-68-2 |
| Molecular formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular weight | 4113.6 g/mol |
| Purity | ≥98% (HPLC) |
| Physical form | Lyophilized powder |
| Storage | −20 °C, desiccated, protected from light |
Sequence
Reported research areas
- GLP-1 receptor (GLP-1R) signaling and cAMP pathway assays
- Peptide lipidation and albumin-binding structure-activity studies
- Comparative incretin-receptor pharmacology
- Analytical method development and reference standardization
Credible sources
- PubChem — Semaglutide
- PubMed — Semaglutide GLP-1 receptor literature
- PubMed — peptide lipidation and incretin analogs
COA with every lot
Each Semaglutide lot is characterized by reversed-phase HPLC for purity and by mass spectrometry for identity, then documented in a per-lot Certificate of Analysis. Unique lot numbers tie the vial back to its synthesis batch and analytical data.
- RP-HPLC purity result (≥98% (HPLC))
- Mass-spectrometry identity confirmation
- Appearance, molecular weight, and storage
- Lot number and testing status
Specimen Certificate of Analysis
| Product | Semaglutide (reference) |
| Lot | HXR-2406-109 |
| Purity (RP-HPLC) | 98%+ |
| Identity (MS) | Confirmed · 4113.6 g/mol |
| Appearance | Lyophilized powder |
| Storage | −20 °C, desiccated |
Representative document. Each lot has its own COA — these are quality documents, not medical claims.
Loading verified reviews…
Reviews come only from buyers we can match to a real order, and each is moderated before it appears. We never publish fabricated or incentivized reviews.